MarketCap
Facebook
X
TelegramQuarterly report 2025-Q3
added 11-14-2025
ENDRA Life Sciences Operating Income 2011-2025 | NDRA
Operating profit (also called operating income or profit from core activities) is a financial metric that reflects a company's profit from its main operational activities before interest expenses and taxes are taken into account.
FormulaOperating profit = Revenue – Operating expensesFeatures of the metric
- Evaluates business efficiency
Shows how well the company controls its production and administrative costs. - Independent of financial structure
Excludes the impact of debt burden (interest) and taxes, allowing objective comparison of companies. - Main source for growth
High operating profit provides resources for investments, business expansion, and increased competitiveness.
If a company shows strong operating profit, it signals to investors that the core business is operating efficiently, even if net profit is temporarily reduced due to debt or tax burden.
Annual Operating Income ENDRA Life Sciences
| 2024 | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 | 2015 | 2014 | 2013 | 2012 | 2011 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| -10.8 M | -10.5 M | -13.2 M | -11.5 M | -11.5 M | -10.8 M | -9.02 M | -4.63 M | -1.79 M | - | - | - | - | - |
All numbers in USD currency
Indicator range from annual reports
| Maximum | Minimum | Average |
|---|---|---|
| -1.79 M | -13.2 M | -9.31 M |
Quarterly Operating Income ENDRA Life Sciences
| 2025-Q3 | 2025-Q2 | 2025-Q1 | 2024-Q4 | 2024-Q3 | 2024-Q2 | 2024-Q1 | 2023-Q4 | 2023-Q3 | 2023-Q2 | 2023-Q1 | 2022-Q4 | 2022-Q3 | 2022-Q2 | 2022-Q1 | 2021-Q4 | 2021-Q3 | 2021-Q2 | 2021-Q1 | 2020-Q4 | 2020-Q3 | 2020-Q2 | 2020-Q1 | 2019-Q4 | 2019-Q3 | 2019-Q2 | 2019-Q1 | 2018-Q4 | 2018-Q3 | 2018-Q2 | 2018-Q1 | 2017-Q4 | 2017-Q3 | 2017-Q2 | 2017-Q1 | 2016-Q4 | 2016-Q3 | 2016-Q2 | 2016-Q1 | 2015-Q4 | 2015-Q3 | 2015-Q2 | 2015-Q1 | 2014-Q4 | 2014-Q3 | 2014-Q2 | 2014-Q1 | 2013-Q4 | 2013-Q3 | 2013-Q2 | 2013-Q1 | 2012-Q4 | 2012-Q3 | 2012-Q2 | 2012-Q1 | 2011-Q4 | 2011-Q3 | 2011-Q2 | 2011-Q1 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| -1.37 M | -1.3 M | -1.47 M | - | -1.51 M | -2.23 M | -2.78 M | - | -3.13 M | -2.99 M | -2.94 M | - | -3.42 M | -3.57 M | -2.86 M | - | -2.65 M | -3.2 M | -2.58 M | - | -3.26 M | -2.89 M | -3.1 M | - | -2.64 M | -2.33 M | -2.75 M | - | -2.36 M | -1.82 M | -2.84 M | - | -911 K | -1.06 M | -361 K | - | -605 K | -494 K | -373 K | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - |
All numbers in USD currency
Indicator range from quarterly reporting
| Maximum | Minimum | Average |
|---|---|---|
| -361 K | -3.57 M | -2.19 M |
Operating Income of other stocks in the Diagnostics research industry
| Issuer | Operating Income | Price | % 24h | Market Cap | Country | |
|---|---|---|---|---|---|---|
 |
Brainsway Ltd.
BWAY
|
-5 M | $ 16.64 | -1.25 % | $ 99.4 M |  Israel |
 |
Centogene N.V.
CNTG
|
-46 M | - | -6.23 % | $ 30.6 M |  Germany |
|
Akumin
AKU
|
-28.1 M | - | -17.87 % | $ 25.9 M |  Canada |
 |
DarioHealth Corp.
DRIO
|
-56.2 M | $ 11.98 | 0.76 % | $ 340 M | Israel |
 |
DexCom
DXCM
|
598 M | $ 66.7 | -0.39 % | $ 25.7 B |  USA |
 |
Burning Rock Biotech Limited
BNR
|
-797 M | $ 16.71 | 6.1 % | $ 180 M |  China |
 |
Exact Sciences Corporation
EXAS
|
-876 M | $ 101.53 | 0.03 % | $ 18.8 B | USA |
 |
Accelerate Diagnostics
AXDX
|
-14 M | - | -61.36 % | $ 2.46 M | USA |
 |
Biocept
BIOC
|
-32 M | - | -13.05 % | $ 7.29 M | USA |
 |
BioNano Genomics
BNGO
|
-104 M | $ 1.59 | -1.91 % | $ 2.02 M | USA |
 |
IQVIA Holdings
IQV
|
2.2 B | $ 222.65 | 0.18 % | $ 40.4 B | USA |
 |
Castle Biosciences
CSTL
|
8.67 M | $ 38.47 | -0.41 % | $ 1.07 B | USA |
 |
Chembio Diagnostics
CEMI
|
-23.6 M | - | 0.22 % | $ 16.8 M | USA |
 |
Danaher Corporation
DHR
|
4.86 B | $ 226.5 | 0.08 % | $ 166 B | USA |
 |
Fulgent Genetics
FLGT
|
-73.9 M | $ 26.81 | -1.22 % | $ 811 M | USA |
 |
Global Cord Blood Corporation
CO
|
609 M | - | - | $ 399 M | China |
 |
Genetron Holdings Limited
GTH
|
-518 M | - | 0.12 % | $ 80.1 M | China |
 |
DermTech
DMTK
|
-104 M | - | -11.32 % | $ 2.94 M | USA |
 |
Myriad Genetics
MYGN
|
-124 M | $ 7.01 | -2.77 % | $ 635 M | USA |
 |
NeoGenomics
NEO
|
-92.1 M | $ 12.08 | 1.94 % | $ 1.53 B | USA |
 |
Neogen Corporation
NEOG
|
-1.06 B | $ 6.83 | -0.51 % | $ 1.48 B | USA |
 |
CareDx, Inc
CDNA
|
-203 M | $ 19.96 | -2.92 % | $ 1.07 B | USA |
 |
Celcuity
CELC
|
-113 M | $ 102.35 | -2.76 % | $ 4.04 B | USA |
 |
Enzo Biochem
ENZ
|
-12.4 M | - | -8.98 % | $ 14.8 K | USA |
 |
Anixa Biosciences
ANIX
|
-13.8 M | $ 3.56 | -0.7 % | $ 114 K | USA |
 |
Co-Diagnostics
CODX
|
-42.7 M | $ 0.31 | -9.02 % | $ 9.1 M | USA |
 |
Pacific Biosciences of California
PACB
|
-334 M | $ 2.11 | -0.71 % | $ 535 M | USA |
 |
Koninklijke Philips N.V.
PHG
|
553 M | $ 26.56 | -0.23 % | $ 20 B |  Niderland |
 |
Guardant Health
GH
|
-444 M | $ 104.86 | 2.73 % | $ 12.9 B | USA |
 |
Precipio
PRPO
|
-7.62 M | $ 24.68 | -1.14 % | $ 32 M | USA |
 |
QIAGEN N.V.
QGEN
|
97.7 M | $ 45.24 | 0.04 % | $ 10.1 B | Niderland |
 |
Aspira Women's Health
AWH
|
-32.8 M | - | -6.19 % | $ 10.5 M | USA |
 |
Sotera Health Company
SHC
|
298 M | $ 16.81 | -0.15 % | $ 4.75 B | USA |
 |
Heska Corporation
HSKA
|
-20.3 M | - | - | $ 1.31 B | USA |
 |
Soleno Therapeutics
SLNO
|
-188 M | $ 51.43 | -1.1 % | $ 2.07 B | USA |
 |
HTG Molecular Diagnostics
HTGM
|
-20.8 M | - | -20.0 % | $ 1.06 M | USA |
 |
Illumina
ILMN
|
-833 M | $ 134.29 | -0.43 % | $ 21.4 B | USA |
 |
Charles River Laboratories International
CRL
|
227 M | $ 196.55 | 1.82 % | $ 10.1 B | USA |
 |
Quotient Limited
QTNT
|
-82.7 M | - | -11.32 % | $ 1.1 M |  Schweiz |
 |
Thermo Fisher Scientific
TMO
|
7.34 B | $ 567.34 | -0.76 % | $ 217 B | USA |
 |
Trinity Biotech plc
TRIB
|
6.62 M | $ 1.08 | 0.93 % | $ 61.9 M |  Irlanda |
 |
Twist Bioscience Corporation
TWST
|
-136 M | $ 31.12 | 0.61 % | $ 1.86 B | USA |
 |
Quest Diagnostics Incorporated
DGX
|
1.35 B | $ 183.54 | 0.54 % | $ 20.4 B | USA |
|
Biodesix
BDSX
|
-34.5 M | $ 7.76 | -1.15 % | $ 1.01 B | USA |